Efficacy and safety of cilnidipine for the treatment of patients with mild to moderate essential hypertension

Objective: To investigate the efficacy and safety of cilnidipine in the treatment of mild to moderate essential hypertension.Methods: The study design was randomized,controlled,double blind and double simulated.One half of 48 patients(n=24) were orally given cilnidipine and amlodipine besylate mimesis tablet.The initial dose of cilnidipine was 5 mg per day;after 4 weeks,the dose was increased to 10 mg per day until the end of the study if the diastolic blood pressure was equal or above 90 mmHg.Other patients(n=24) were orally given amlodipine besylate and cilnidipine mimesis tablet in the same administration and doses.Results: At 8 weeks after treatment,systolic blood pressure was decreased by(11.13±7.31)mmHg and(16.10±7.68)mmHg in cilnidipine and amlodipine groups(P0.05),respectively. The diastolic blood pressure was decreased by(11.01±4.17)mmHg and(13.27±4.57)mmHg in cilnidipine and amlodipine group,respectively.There were significant differences in systolic and diastolic blood pressure before and after both treatments.No serious adverse reaction occurred after 2 treatments;however,the adverse reaction occurred in 5 patients in either cilnidipine or amlodipine group(P0.05),respectively.Conclusion: Oral cilnidipine once daily is effective and safe in the treatment of mild to moderate essential hypertension.